Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
DEA proposes placing tianeptine in Schedule I, making it illegal to possess, dispense, or compound. This affects pharmacies currently handling tianeptine-containing products.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmacies (independent, retail chains, compounding, long-term-care) that stock, dispense, or compound tianeptine. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective upon final rule publication (typically 30 days after proposal); monitor Federal Register for final date.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Tianeptine is proposed to be classified as a Schedule I controlled substance with no accepted medical use.
Who it affects
All pharmacies (independent, retail chains, compounding, long-term-care) that stock, dispense, or compound tianeptine.
What you must do
Immediately cease dispensing, compounding, or distributing tianeptine; secure and dispose of existing inventory per DEA guidelines.
Deadline
Effective upon final rule publication (typically 30 days after proposal); monitor Federal Register for final date.
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order